This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
About Zinforo

About Zinforo

OverviewExtended spectrum coverageDosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosingEfficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric SafetyClinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE studySupport & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: Treat the majority of patients with simple dosing and a flexible infusion timeDose in adults and adolescents aged 12 to <18 years with a bodyweight of ≥ 33 kg and CrCL > 50 mL/min**¥1

No dosage adjustment is required for:

  • Elderly patients with CrCL > 50 ml/min
  • Adult patients according to body weight
  • Patients with hepatic impairment or mild renal impairment
Based on PK/PD analyses, the recommended dose regimen for treatment of cSSTI in adults due to confirmed or suspected S.aureus for which the Zinforo MIC is 2 or 4 mg/L is 600 mg every 8 hours using 2-hour infusions†1 Zinforo can be used in patients with varying degrees of renal impairment1Dosage in adults and adolescents aged from 12 to <18 years with bodyweight ≥ 33 kg and CrCL ≤ 50 mL/min**¥1Zinforo PK/PD

Zinforo has relatively low protein binding (<20%), and using data comparing protein binding with rate of penetration to the site of infection, is predicted to have a rapid penetration rate5,6

At a dose of 600 mg every 12 hours and an MIC of 1 mg/L:​​​​​​​

  • 98.1% of patients would be expected to achieve a target free drug concentration above the MIC in plasma; for 600 mg every 8 hours, the proportion would be 100%6
  • 81.7% would be expected to achieve a target MIC in ELF6
Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI¶1,5,7,8 Learn more Loading

*Applies only for standard dose regimens in adults and paediatrics, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis)1
†Infusion times of < 60 minutes and high-dose recommendations are based on PK/PD analyses only.1
‡ Dose recommendations for the treatment of cSSTI caused by S.aureus for which the Zinforo MIC is ≤ 1 mg/L
** Calculated using the Cockcroft-Gault formula1
 Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
​​​​​​​¥Calculated using the Schwartz formula for paediatric patients (in mL/min/1.73 m2). Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.
§Ceftaroline is haemodialyzable; thus Zinforo hould be administered after haemodialysis on haemodialysis days.

Abbreviations

CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CrCL, creatinine clearance; MIC, minimum inhibitory concentration.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References

ZINFORO. Summary of Product CharacteristicsLiscio JL, et al. Int J Antimicrob Agents 2015;46:266–7Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9Mazuski JE, et al. Surg Infect 2017;18:1–76Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7Riccobene TA, et al. Antimicrob Agents Chemother 2016;60:5849-57Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18 Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
PP-ZFO-GBR-0221. September 2021
 Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials

 View tolerability profile LoadingDiscover specific information on the use of Zinforo in neonates, infants and children here:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​